{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:43:54Z","timestamp":1792446234609,"version":"4.5.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41585-025-01112-9","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:02:48Z","timestamp":1767780168000},"page":"319-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["SRD5A2 and emerging therapies in androgen-driven disorders"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-2912","authenticated-orcid":false,"given":"Zongwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1521-9608","authenticated-orcid":false,"given":"Boqing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Sharkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5356-2558","authenticated-orcid":false,"given":"Aria F.","family":"Olumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"1112_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41585-018-0087-9","volume":"15","author":"WN Brennen","year":"2018","unstructured":"Brennen, W. N. & Isaacs, J. T. Mesenchymal stem cells and the embryonic reawakening theory of BPH. Nat. Rev. Urol. 15, 703\u2013715 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"1112_CR2","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1038\/ijir.2008.55","volume":"20","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn, C. G. Pathology of benign prostatic hyperplasia. Int. J. Impot. Res. 20, S11\u2013S18 (2008).","journal-title":"Int. J. Impot. Res."},{"key":"1112_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pop.2019.02.003","volume":"46","author":"RC Langan","year":"2019","unstructured":"Langan, R. C. Benign prostatic hyperplasia. Prim. Care 46, 223\u2013232 (2019).","journal-title":"Prim. Care"},{"key":"1112_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ucl.2009.07.003","volume":"36","author":"W Bushman","year":"2009","unstructured":"Bushman, W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol. Clin. North. Am. 36, 403\u2013415 (2009).","journal-title":"Urol. Clin. North. Am."},{"key":"1112_CR5","unstructured":"NIDDK. Urologic diseases in America Annual Data Report: benign prostatic hyperplasia and associated lower urinary tract symptoms. NIDDK www.niddk.nih.gov\/about-niddk\/strategic-plans-reports\/urologic-diseases-in-america (2024)."},{"key":"1112_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41585-024-00878-8","volume":"21","author":"M Bitaraf","year":"2024","unstructured":"Bitaraf, M., Ramasamy, R., Punnen, S. & Sharifi, N. Elevated periprostatic androgens, sneaky testosterone and its implications. Nat. Rev. Urol. 21, 754\u2013760 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"1112_CR7","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/nrdp.2016.31","volume":"2","author":"B Chughtai","year":"2016","unstructured":"Chughtai, B. et al. Benign prostatic hyperplasia. Nat. Rev. Dis. Primers 2, 16031 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1112_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ajur.2017.11.005","volume":"5","author":"EH Kim","year":"2018","unstructured":"Kim, E. H., Brockman, J. A. & Andriole, G. L. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J. Urol. 5, 28\u201332 (2018).","journal-title":"Asian J. Urol."},{"key":"1112_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0197-2456(02)00263-5","volume":"24","author":"OM Bautista","year":"2003","unstructured":"Bautista, O. M. et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control. Clin. Trials 24, 224\u2013243 (2003).","journal-title":"Control. Clin. Trials"},{"key":"1112_CR10","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.juro.2010.11.060","volume":"185","author":"SA Kaplan","year":"2011","unstructured":"Kaplan, S. A., Lee, J. Y., Meehan, A. G. & Kusek, J. W.MTOPS Research Group Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J. Urol. 185, 1369\u20131373 (2011).","journal-title":"J. Urol."},{"key":"1112_CR11","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell, J. D. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 349, 2387\u20132398 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.juro.2008.05.004","volume":"180","author":"SA Kaplan","year":"2008","unstructured":"Kaplan, S. A. et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J. Urol. 180, 1030\u20131032 (2008). discussion 1032\u20131033.","journal-title":"J. Urol."},{"key":"1112_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0022-5347(05)00041-8","volume":"175","author":"SA Kaplan","year":"2006","unstructured":"Kaplan, S. A. et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J. Urol. 175, 217\u2013220 (2006). discussion 220\u2013221.","journal-title":"J. Urol."},{"key":"1112_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJM199608223350801","volume":"335","author":"H Lepor","year":"1996","unstructured":"Lepor, H. et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. veterans affairs cooperative studies benign prostatic hyperplasia study group. N. Engl. J. Med. 335, 533\u2013539 (1996).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1210\/edrv-8-3-338","volume":"8","author":"GR Cunha","year":"1987","unstructured":"Cunha, G. R. et al. The endocrinology and developmental biology of the prostate. Endocr. Rev. 8, 338\u2013362 (1987).","journal-title":"Endocr. Rev."},{"key":"1112_CR16","doi-asserted-by":"publisher","first-page":"530121","DOI":"10.1155\/2012\/530121","volume":"2012","author":"F Azzouni","year":"2012","unstructured":"Azzouni, F., Godoy, A., Li, Y. & Mohler, J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv. Urol. 2012, 530121 (2012).","journal-title":"Adv. Urol."},{"key":"1112_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1210\/jcem-38-1-113","volume":"38","author":"PK Siiteri","year":"1974","unstructured":"Siiteri, P. K. & Wilson, J. D. Testosterone formation and metabolism during male sexual differentiation in the human embryo. J. Clin. Endocrinol. Metab. 38, 113\u2013125 (1974).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1112_CR18","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1126\/science.186.4170.1213","volume":"186","author":"J Imperato-McGinley","year":"1974","unstructured":"Imperato-McGinley, J., Guerrero, L., Gautier, T. & Peterson, R. E. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186, 1213\u20131215 (1974).","journal-title":"Science"},{"key":"1112_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ajur.2019.10.003","volume":"7","author":"RE Vickman","year":"2020","unstructured":"Vickman, R. E. et al. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: a review. Asian J. Urol. 7, 191\u2013202 (2020).","journal-title":"Asian J. Urol."},{"key":"1112_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/path.4985","volume":"243","author":"Z Wang","year":"2017","unstructured":"Wang, Z. et al. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5\u03b1-reductase 2. J. Pathol. 243, 457\u2013467 (2017).","journal-title":"J. Pathol."},{"key":"1112_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrurol.2010.207","volume":"8","author":"CK Ho","year":"2011","unstructured":"Ho, C. K. & Habib, F. K. Estrogen and androgen signaling in the pathogenesis of BPH. Nat. Rev. Urol. 8, 29\u201341 (2011).","journal-title":"Nat. Rev. Urol."},{"key":"1112_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.4158\/EP12108.RA","volume":"18","author":"AM Traish","year":"2012","unstructured":"Traish, A. M. 5\u03b1-reductases in human physiology: an unfolding story. Endocr. Pract. 18, 965\u2013975 (2012).","journal-title":"Endocr. Pract."},{"key":"1112_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1159\/000020181","volume":"37","author":"G Bartsch","year":"2000","unstructured":"Bartsch, G., Rittmaster, R. S. & Klocker, H. Dihydrotestosterone and the concept of 5\u03b1-reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 37, 367\u2013380 (2000).","journal-title":"Eur. Urol."},{"key":"1112_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/pros.2990020105","volume":"2","author":"JE McNeal","year":"1981","unstructured":"McNeal, J. E. The zonal anatomy of the prostate. Prostate 2, 35\u201349 (1981).","journal-title":"Prostate"},{"key":"1112_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/354159a0","volume":"354","author":"S Andersson","year":"1991","unstructured":"Andersson, S., Berman, D. M., Jenkins, E. P. & Russell, D. W. Deletion of steroid 5\u03b1-reductase 2 gene in male pseudohermaphroditism. Nature 354, 159\u2013161 (1991).","journal-title":"Nature"},{"key":"1112_CR26","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJM197905313002201","volume":"300","author":"J Imperato-McGinley","year":"1979","unstructured":"Imperato-McGinley, J., Peterson, R. E., Gautier, T. & Sturla, E. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5\u03b1-reductase deficiency. N. Engl. J. Med. 300, 1233\u20131237 (1979).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/path.6283","volume":"263","author":"C Sharkey","year":"2024","unstructured":"Sharkey, C. et al. Enhanced prostatic Esr1+ luminal epithelial cells in the absence of SRD5A2. J. Pathol. 263, 300\u2013314 (2024).","journal-title":"J. Pathol."},{"key":"1112_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajpath.2015.01.001","volume":"185","author":"JT Isaacs","year":"2015","unstructured":"Isaacs, J. T. Lessons learned about prostatic transformation from the age-related methylation of 5\u03b1-reductase type 2 gene. Am. J. Pathol. 185, 614\u2013616 (2015).","journal-title":"Am. J. Pathol."},{"key":"1112_CR29","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3389\/fphys.2017.00688","volume":"8","author":"XT Zeng","year":"2017","unstructured":"Zeng, X. T. et al. Association between SRD5A2 rs523349 and rs9282858 polymorphisms and risk of benign prostatic hyperplasia: a meta-analysis. Front. Physiol. 8, 688 (2017).","journal-title":"Front. Physiol."},{"key":"1112_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19249-z","volume":"11","author":"Q Xiao","year":"2020","unstructured":"Xiao, Q. et al. Structure of human steroid 5\u03b1-reductase 2 with the anti-androgen drug finasteride. Nat. Commun. 11, 5430 (2020).","journal-title":"Nat. Commun."},{"key":"1112_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.juro.2013.03.024","volume":"190","author":"X Gu","year":"2013","unstructured":"Gu, X. et al. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5\u03b1-reductase inhibitors and \u03b1-adrenergic receptor antagonists. J. Urol. 190, 615\u2013619 (2013).","journal-title":"J. Urol."},{"key":"1112_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.diff.2011.04.004","volume":"82","author":"Z Wang","year":"2011","unstructured":"Wang, Z. & Olumi, A. F. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation 82, 261\u2013271 (2011).","journal-title":"Differentiation"},{"key":"1112_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/pros.2990200105","volume":"20","author":"BC Murphy","year":"1992","unstructured":"Murphy, B. C., Pienta, K. J. & Coffey, D. S. Effects of extracellular matrix components and dihydrotestosterone on the structure and function of human prostate cancer cells. Prostate 20, 29\u201341 (1992).","journal-title":"Prostate"},{"key":"1112_CR34","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jsbmb.2009.10.015","volume":"118","author":"SJ Ellem","year":"2010","unstructured":"Ellem, S. J. & Risbridger, G. P. Aromatase and regulating the estrogen:androgen ratio in the prostate gland. J. Steroid Biochem. Mol. Biol. 118, 246\u2013251 (2010).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1112_CR35","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M. et al. Proteomics. tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"1112_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1677\/JME-07-0053","volume":"39","author":"GP Risbridger","year":"2007","unstructured":"Risbridger, G. P., Ellem, S. J. & McPherson, S. J. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J. Mol. Endocrinol. 39, 183\u2013188 (2007).","journal-title":"J. Mol. Endocrinol."},{"key":"1112_CR37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","volume":"327","author":"GJ Gormley","year":"1992","unstructured":"Gormley, G. J. et al. The effect of finasteride in men with benign prostatic hyperplasia. the finasteride study group. N. Engl. J. Med. 327, 1185\u20131191 (1992).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR38","first-page":"535","volume":"5","author":"AB Smith","year":"2009","unstructured":"Smith, A. B. & Carson, C. C. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther. Clin. Risk Manag. 5, 535\u2013545 (2009).","journal-title":"Ther. Clin. Risk Manag."},{"key":"1112_CR39","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","volume":"49","author":"CR Chapple","year":"2006","unstructured":"Chapple, C. R. & Roehrborn, C. G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur. Urol. 49, 651\u2013658 (2006).","journal-title":"Eur. Urol."},{"key":"1112_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJM199802263380901","volume":"338","author":"JD McConnell","year":"1998","unstructured":"McConnell, J. D. et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. finasteride long-term efficacy and safety study group. N. Engl. J. Med. 338, 557\u2013563 (1998).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR41","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.eururo.2007.11.026","volume":"54","author":"JC Nickel","year":"2008","unstructured":"Nickel, J. C. et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur. Urol. 54, 1379\u20131384 (2008).","journal-title":"Eur. Urol."},{"key":"1112_CR42","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1210\/jc.2005-2799","volume":"91","author":"JK Parsons","year":"2006","unstructured":"Parsons, J. K. et al. Metabolic factors associated with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 91, 2562\u20132568 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1112_CR43","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrurol.2016.168","volume":"13","author":"C De Nunzio","year":"2016","unstructured":"De Nunzio, C., Presicce, F. & Tubaro, A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat. Rev. Urol. 13, 613\u2013626 (2016).","journal-title":"Nat. Rev. Urol."},{"key":"1112_CR44","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41585-025-01011-z","volume":"22","author":"S Lee","year":"2025","unstructured":"Lee, S., Sfanos, K. & Singla, N. The role of the urinary microbiome in genitourinary cancers. Nat. Rev. Urol. 22, 544\u2013561 (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1112_CR45","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41585-019-0250-y","volume":"16","author":"S Altm\u00e4e","year":"2019","unstructured":"Altm\u00e4e, S., Franasiak, J. M. & M\u00e4ndar, R. The seminal microbiome in health and disease. Nat. Rev. Urol. 16, 703\u2013721 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"1112_CR46","doi-asserted-by":"publisher","first-page":"842008","DOI":"10.3389\/fimmu.2022.842008","volume":"13","author":"D Cao","year":"2022","unstructured":"Cao, D. et al. Immune cell proinflammatory microenvironment and androgen-related metabolic regulation during benign prostatic hyperplasia in aging. Front. Immunol. 13, 842008 (2022).","journal-title":"Front. Immunol."},{"key":"1112_CR47","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.euf.2023.10.015","volume":"10","author":"R Al-Faouri","year":"2024","unstructured":"Al-Faouri, R. et al. Effect of TNF-\u03b1 inhibitor therapy on growth of the prostate gland. Eur. Urol. Focus. 10, 641\u2013647 (2024).","journal-title":"Eur. Urol. Focus."},{"key":"1112_CR48","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ajpath.2014.11.020","volume":"185","author":"R Ge","year":"2015","unstructured":"Ge, R. et al. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am. J. Pathol. 185, 870\u2013882 (2015).","journal-title":"Am. J. Pathol."},{"key":"1112_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/srep42893","volume":"7","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5\/STAT5\/CCND1 signaling pathway. Sci. Rep. 7, 42893 (2017).","journal-title":"Sci. Rep."},{"key":"1112_CR50","doi-asserted-by":"publisher","first-page":"18376","DOI":"10.1074\/jbc.M112.355164","volume":"287","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation. J. Biol. Chem. 287, 18376\u201318385 (2012).","journal-title":"J. Biol. Chem."},{"key":"1112_CR51","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fimmu.2024.1494476","volume":"15","author":"NA Lanman","year":"2025","unstructured":"Lanman, N. A. et al. Infiltrating lipid-rich macrophage subpopulations identified as a regulator of increasing prostate size in human benign prostatic hyperplasia. Front. Immunol. 15, 2024 (2025).","journal-title":"Front. Immunol."},{"key":"1112_CR52","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/pros.23319","volume":"77","author":"S Inamura","year":"2017","unstructured":"Inamura, S. et al. Appearance of high endothelial venule-like vessels in benign prostatic hyperplasia is associated with lower urinary tract symptoms. Prostate 77, 794\u2013802 (2017).","journal-title":"Prostate"},{"key":"1112_CR53","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/pros.22785","volume":"74","author":"O Lin-Tsai","year":"2014","unstructured":"Lin-Tsai, O. et al. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate 74, 669\u2013679 (2014).","journal-title":"Prostate"},{"key":"1112_CR54","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.ajpath.2025.08.011","volume":"195","author":"C Sharkey","year":"2025","unstructured":"Sharkey, C. et al. Stromal steroid 5 alpha-reductase 2 promotes prostate growth through WNT5A-lymphoid enhancer-binding factor 1-insulin-like growth factor 1 signaling in benign prostatic hyperplasia. Am. J. Pathol. 195, 2411\u20132430 (2025).","journal-title":"Am. J. Pathol."},{"key":"1112_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29719-1","volume":"13","author":"RE Vickman","year":"2022","unstructured":"Vickman, R. E. et al. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nat. Commun. 13, 2133 (2022).","journal-title":"Nat. Commun."},{"key":"1112_CR56","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41391-020-0208-4","volume":"23","author":"B Xue","year":"2020","unstructured":"Xue, B. et al. Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. Prostate Cancer Prostatic Dis. 23, 465\u2013474 (2020).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1112_CR57","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2353\/ajpath.2007.070285","volume":"171","author":"W Li","year":"2007","unstructured":"Li, W., Wu, C. L., Febbo, P. G. & Olumi, A. F. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am. J. Pathol. 171, 1189\u20131198 (2007).","journal-title":"Am. J. Pathol."},{"key":"1112_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000525119","volume":"16","author":"RL Batista","year":"2022","unstructured":"Batista, R. L. & Mendonca, B. B. The molecular basis of 5\u03b1-reductase type 2 deficiency. Sex. Dev. 16, 171\u2013183 (2022).","journal-title":"Sex. Dev."},{"key":"1112_CR59","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1021\/ja953069t","volume":"118","author":"HG Bull","year":"1996","unstructured":"Bull, H. G. et al. Mechanism-based inhibition of human steroid 5\u03b1-reductase by finasteride: enzyme-catalyzed formation of NADP\u2212dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. 118, 2359\u20132365 (1996).","journal-title":"J. Am. Chem. Soc."},{"key":"1112_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/sj.pcan.4500931","volume":"10","author":"R Wurzel","year":"2007","unstructured":"Wurzel, R., Ray, P., Major-Walker, K., Shannon, J. & Rittmaster, R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 10, 149\u2013154 (2007).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1112_CR61","first-page":"1077","volume":"10","author":"AW Hsing","year":"2001","unstructured":"Hsing, A. W. et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomark. Prev. 10, 1077\u20131082 (2001).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1112_CR62","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S0140-6736(98)11282-5","volume":"354","author":"NM Makridakis","year":"1999","unstructured":"Makridakis, N. M. et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354, 975\u2013978 (1999).","journal-title":"Lancet"},{"key":"1112_CR63","first-page":"3973","volume":"55","author":"JK Reichardt","year":"1995","unstructured":"Reichardt, J. K. et al. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 55, 3973\u20133975 (1995).","journal-title":"Cancer Res."},{"key":"1112_CR64","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1097\/01.ju.0000056152.57018.31","volume":"169","author":"Z Li","year":"2003","unstructured":"Li, Z. et al. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J. Urol. 169, 2378\u20132381 (2003).","journal-title":"J. Urol."},{"key":"1112_CR65","first-page":"8660","volume":"10","author":"LL Zhang","year":"2017","unstructured":"Zhang, L. L. et al. Associations of SRD5A2\/CYP17\/CYP19\/VDR gene polymorphisms with the development and clinical progression of benign prostatic hyperplasia: a case-control study in northern Chinese population. Int. J. Clin. Exp. Pathol. 10, 8660\u20138676 (2017).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"1112_CR66","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00008571-200007000-00004","volume":"10","author":"NM Makridakis","year":"2000","unstructured":"Makridakis, N. M., di Salle, E. & Reichardt, J. K. Biochemical and pharmacogenetic dissection of human steroid 5\u03b1-reductase type II. Pharmacogenetics 10, 407\u2013413 (2000).","journal-title":"Pharmacogenetics"},{"key":"1112_CR67","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.1038\/sj.onc.1207922","volume":"23","author":"N Makridakis","year":"2004","unstructured":"Makridakis, N., Akalu, A. & Reichardt, J. K. Identification and characterization of somatic steroid 5\u03b1-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene 23, 7399\u20137405 (2004).","journal-title":"Oncogene"},{"key":"1112_CR68","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/pros.21348","volume":"71","author":"Y Niu","year":"2011","unstructured":"Niu, Y. et al. Reduced levels of 5\u03b1-reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate 71, 1317\u20131324 (2011).","journal-title":"Prostate"},{"key":"1112_CR69","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00345-018-2422-4","volume":"37","author":"PM Kang","year":"2019","unstructured":"Kang, P. M. et al. Correlation between 5-\u03b1 reductase type 2 protein expression and methylation of 5-\u03b1 reductase type 2 promotor gene of benign prostatic hyperplasia. World J. Urol. 37, 709\u2013718 (2019).","journal-title":"World J. Urol."},{"key":"1112_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15913-6","volume":"11","author":"D Liu","year":"2020","unstructured":"Liu, D. et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat. Commun. 11, 1987 (2020).","journal-title":"Nat. Commun."},{"key":"1112_CR71","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.juro.2015.04.079","volume":"194","author":"SK Bechis","year":"2015","unstructured":"Bechis, S. K. et al. Age and obesity promote methylation and suppression of 5\u03b1-reductase 2: implications for personalized therapy of benign prostatic hyperplasia. J. Urol. 194, 1031\u20131037 (2015).","journal-title":"J. Urol."},{"key":"1112_CR72","first-page":"197","volume":"6","author":"DB Joseph","year":"2018","unstructured":"Joseph, D. B., Strand, D. W. & Vezina, C. M. DNA methylation in development and disease: an overview for prostate researchers. Am. J. Clin. Exp. Urol. 6, 197\u2013218 (2018).","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"1112_CR73","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.juro.2014.01.114","volume":"192","author":"SK Bechis","year":"2014","unstructured":"Bechis, S. K., Otsetov, A. G., Ge, R. & Olumi, A. F. Personalized medicine for the management of benign prostatic hyperplasia. J. Urol. 192, 16\u201323 (2014).","journal-title":"J. Urol."},{"key":"1112_CR74","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4103\/aja.aja_63_20","volume":"23","author":"ZM Lin","year":"2021","unstructured":"Lin, Z. M., Fan, D. D., Jin, S., Liu, Z. L. & Niu, Y. N. Methylated CpG dinucleotides in the 5-\u03b1 reductase 2 gene may explain finasteride resistance in benign prostatic enlargement patients. Asian J. Androl. 23, 266\u2013272 (2021).","journal-title":"Asian J. Androl."},{"key":"1112_CR75","unstructured":"TheHumanProteinAtlas. SRD5A2 tissue expression. proteinatlas.org https:\/\/www.proteinatlas.org\/ENSG00000277893-SRD5A2\/tissue (2025)."},{"key":"1112_CR76","doi-asserted-by":"publisher","first-page":"102992","DOI":"10.1016\/j.critrevonc.2020.102992","volume":"151","author":"C Buonerba","year":"2020","unstructured":"Buonerba, C. et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 151, 102992 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1112_CR77","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0228","volume":"12","author":"S Torabinejad","year":"2023","unstructured":"Torabinejad, S. et al. The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications. Eur. Thyroid. J. 12, e220228 (2023).","journal-title":"Eur. Thyroid. J."},{"key":"1112_CR78","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"GTEx Consortium","year":"2020","unstructured":"GTEx Consortium The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318\u20131330 (2020).","journal-title":"Science"},{"key":"1112_CR79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev.bi.63.070194.000325","volume":"63","author":"DW Russell","year":"1994","unstructured":"Russell, D. W. & Wilson, J. D. Steroid 5\u03b1-reductase: two genes\/two enzymes. Annu. Rev. Biochem. 63, 25\u201361 (1994).","journal-title":"Annu. Rev. Biochem."},{"key":"1112_CR80","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41585-024-00953-0","volume":"22","author":"PFS Freitas","year":"2025","unstructured":"Freitas, P. F. S., Abdshah, A., McKay, R. R. & Sharifi, N. HSD3B1, prostate cancer mortality and modifiable outcomes. Nat. Rev. Urol. 22, 313\u2013320 (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1112_CR81","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ygcen.2009.08.004","volume":"166","author":"VS Langlois","year":"2010","unstructured":"Langlois, V. S., Zhang, D., Cooke, G. M. & Trudeau, V. L. Evolution of steroid-5\u03b1-reductases and comparison of their function with 5\u03b2-reductase. Gen. Comp. Endocrinol. 166, 489\u2013497 (2010).","journal-title":"Gen. Comp. Endocrinol."},{"key":"1112_CR82","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.beem.2022.101665","volume":"36","author":"R Naamneh Elzenaty","year":"2022","unstructured":"Naamneh Elzenaty, R., du Toit, T. & Fluck, C. E. Basics of androgen synthesis and action. Best. Pract. Res. Clin. Endocrinol. Metab. 36, 101665 (2022).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"1112_CR83","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/1008-682X.123664","volume":"16","author":"K Wang","year":"2014","unstructured":"Wang, K., Fan, D. D., Jin, S., Xing, N. Z. & Niu, Y. N. Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications. Asian J. Androl. 16, 274\u2013279 (2014).","journal-title":"Asian J. Androl."},{"key":"1112_CR84","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eursup.2006.02.004","volume":"5","author":"V Mirone","year":"2006","unstructured":"Mirone, V. et al. Androgens and benign prostatic hyperplasia. Eur. Urol. Suppl. 5, 410\u2013417 (2006).","journal-title":"Eur. Urol. Suppl."},{"key":"1112_CR85","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrurol.2011.67","volume":"8","author":"LP Nacusi","year":"2011","unstructured":"Nacusi, L. P. & Tindall, D. J. Targeting 5\u03b1-reductase for prostate cancer prevention and treatment. Nat. Rev. Urol. 8, 378\u2013384 (2011).","journal-title":"Nat. Rev. Urol."},{"key":"1112_CR86","doi-asserted-by":"publisher","first-page":"28697","DOI":"10.1074\/jbc.271.45.28697","volume":"271","author":"Y Fang","year":"1996","unstructured":"Fang, Y., Fliss, A. E., Robins, D. M. & Caplan, A. J. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J. Biol. Chem. 271, 28697\u201328702 (1996).","journal-title":"J. Biol. Chem."},{"key":"1112_CR87","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1016\/j.ajpath.2014.06.022","volume":"184","author":"M Singh","year":"2014","unstructured":"Singh, M. et al. Stromal androgen receptor in prostate development and cancer. Am. J. Pathol. 184, 2598\u20132607 (2014).","journal-title":"Am. J. Pathol."},{"key":"1112_CR88","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mce.2017.08.016","volume":"465","author":"L Schiffer","year":"2018","unstructured":"Schiffer, L., Arlt, W. & Storbeck, K. H. Intracrine androgen biosynthesis, metabolism and action revisited. Mol. Cell Endocrinol. 465, 4\u201326 (2018).","journal-title":"Mol. Cell Endocrinol."},{"key":"1112_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028840","volume":"6","author":"J Li","year":"2011","unstructured":"Li, J. et al. Androgen regulation of 5\u03b1-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS ONE 6, e28840 (2011).","journal-title":"PLoS ONE"},{"key":"1112_CR90","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1210\/en.2016-1926","volume":"158","author":"\u00c9 Audet-Walsh","year":"2017","unstructured":"Audet-Walsh, \u00c9, Yee, T., Tam, I. S. & Gigu\u00e8re, V. Inverse regulation of DHT synthesis enzymes 5\u03b1-reductase types 1 and 2 by the androgen receptor in prostate cancer. Endocrinology 158, 1015\u20131021 (2017).","journal-title":"Endocrinology"},{"key":"1112_CR91","first-page":"3","volume":"37","author":"RA Davey","year":"2016","unstructured":"Davey, R. A. & Grossmann, M. Androgen receptor structure, function and biology: from bench to bedside. Clin. Biochem. Rev. 37, 3\u201315 (2016).","journal-title":"Clin. Biochem. Rev."},{"key":"1112_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12488","author":"CK Kim","year":"2018","unstructured":"Kim, C. K., Torcaso, A., Asimes, A., Chung, W. C. J. & Pak, T. R. Structural and functional characteristics of oestrogen receptor \u03b2 splice variants: implications for the ageing brain. J. Neuroendocrinol. https:\/\/doi.org\/10.1111\/jne.12488 (2018).","journal-title":"J. Neuroendocrinol."},{"key":"1112_CR93","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diff.2011.04.006","volume":"82","author":"TM Nicholson","year":"2011","unstructured":"Nicholson, T. M. & Ricke, W. A. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82, 184\u2013199 (2011).","journal-title":"Differentiation"},{"key":"1112_CR94","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.diff.2013.02.006","volume":"85","author":"TM Nicholson","year":"2013","unstructured":"Nicholson, T. M., Sehgal, P. D., Drew, S. A., Huang, W. & Ricke, W. A. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment. Differentiation 85, 140\u2013149 (2013).","journal-title":"Differentiation"},{"key":"1112_CR95","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/bcr81","volume":"2","author":"S Nilsson","year":"2000","unstructured":"Nilsson, S. & Gustafsson, J. A. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res. 2, 360\u2013366 (2000).","journal-title":"Breast Cancer Res."},{"key":"1112_CR96","doi-asserted-by":"publisher","first-page":"839005","DOI":"10.3389\/fendo.2022.839005","volume":"13","author":"P Chen","year":"2022","unstructured":"Chen, P., Li, B. & Ou-Yang, L. Role of estrogen receptors in health and disease. Front. Endocrinol. 13, 839005 (2022).","journal-title":"Front. Endocrinol."},{"key":"1112_CR97","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/j.1939-4640.1989.tb00097.x","volume":"10","author":"RS Rittmaster","year":"1989","unstructured":"Rittmaster, R. S., Stoner, E., Thompson, D. L., Nance, D. & Lasseter, K. C. Effect of MK-906, a specific 5 \u03b1-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J. Androl. 10, 259\u2013262 (1989).","journal-title":"J. Androl."},{"key":"1112_CR98","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/pros.2990140106","volume":"14","author":"A Vermeulen","year":"1989","unstructured":"Vermeulen, A., Giagulli, V. A., De Schepper, P., Buntinx, A. & Stoner, E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5\u03b1-reductase in humans. Prostate 14, 45\u201353 (1989).","journal-title":"Prostate"},{"key":"1112_CR99","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2125.1999.00843.x","volume":"47","author":"PO Gisleskog","year":"1999","unstructured":"Gisleskog, P. O., Hermann, D., Hammarlund-Udenaes, M. & Karlsson, M. O. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br. J. Clin. Pharmacol. 47, 53\u201358 (1999).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1112_CR100","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","volume":"60","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn, C. G. et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60, 434\u2013441 (2002).","journal-title":"Urology"},{"key":"1112_CR101","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","volume":"41","author":"BK Park","year":"2001","unstructured":"Park, B. K., Kitteringham, N. R. & O\u2019Neill, P. M. Metabolism of fluorine-containing drugs. Annu. Rev. Pharmacol. Toxicol. 41, 443\u2013470 (2001).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1112_CR102","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.3390\/pr10102054","volume":"10","author":"AS Nair","year":"2022","unstructured":"Nair, A. S. et al. FDA-approved trifluoromethyl group-containing drugs: a review of 20 years. Processes 10, 2054 (2022).","journal-title":"Processes"},{"key":"1112_CR103","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/jamainternmed.2019.0280","volume":"179","author":"RR Sarkar","year":"2019","unstructured":"Sarkar, R. R. et al. Association of treatment with 5\u03b1-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern. Med. 179, 812\u2013819 (2019).","journal-title":"JAMA Intern. Med."},{"key":"1112_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32356-3","volume":"13","author":"M Laanani","year":"2023","unstructured":"Laanani, M., Weill, A., Jollant, F., Zureik, M. & Dray-Spira, R. Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study. Sci. Rep. 13, 5308 (2023).","journal-title":"Sci. Rep."},{"key":"1112_CR105","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0302-2838(03)00198-2","volume":"44","author":"GL Andriole","year":"2003","unstructured":"Andriole, G. L. & Kirby, R. Safety and tolerability of the dual 5\u03b1-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. 44, 82\u201388 (2003).","journal-title":"Eur. Urol."},{"key":"1112_CR106","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1124\/dmd.109.027870","volume":"37","author":"A Lundahl","year":"2009","unstructured":"Lundahl, A., Lennernas, H., Knutson, L., Bondesson, U. & Hedeland, M. Identification of finasteride metabolites in human bile and urine by high-performance liquid chromatography\/tandem mass spectrometry. Drug. Metab. Dispos. 37, 2008\u20132017 (2009).","journal-title":"Drug. Metab. Dispos."},{"key":"1112_CR107","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2165\/00003088-199630010-00002","volume":"30","author":"JF Steiner","year":"1996","unstructured":"Steiner, J. F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin. Pharmacokinet. 30, 16\u201327 (1996).","journal-title":"Clin. Pharmacokinet."},{"key":"1112_CR108","first-page":"S31","volume":"6","author":"JC Nickel","year":"2004","unstructured":"Nickel, J. C. Comparison of clinical trials with finasteride and dutasteride. Rev. Urol. 6, S31\u2013S39 (2004).","journal-title":"Rev. Urol."},{"key":"1112_CR109","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41585-023-00803-5","volume":"21","author":"M Gul","year":"2024","unstructured":"Gul, M. et al. A clinical guide to rare male sexual disorders. Nat. Rev. Urol. 21, 35\u201349 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"1112_CR110","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","volume":"113","author":"AM Traish","year":"2020","unstructured":"Traish, A. M. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil. Steril. 113, 21\u201350 (2020).","journal-title":"Fertil. Steril."},{"key":"1112_CR111","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1517\/14740338.2013.742885","volume":"12","author":"S Gur","year":"2013","unstructured":"Gur, S., Kadowitz, P. J. & Hellstrom, W. J. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin. Drug Saf. 12, 81\u201390 (2013).","journal-title":"Expert Opin. Drug Saf."},{"key":"1112_CR112","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.euf.2024.04.009","volume":"10","author":"A Uleri","year":"2024","unstructured":"Uleri, A. et al. Association of 5\u03b1-reductase inhibitors with depression and suicide: a mini systematic review and meta-analysis. Eur. Urol. Focus 10, 751\u2013753 (2024).","journal-title":"Eur. Urol. Focus"},{"key":"1112_CR113","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/JU.0000000000002332","volume":"207","author":"C Sharkey","year":"2022","unstructured":"Sharkey, C. et al. Zonal growth pattern of the prostate is affected by age and body mass index. J. Urol. 207, 876\u2013884 (2022).","journal-title":"J. Urol."},{"key":"1112_CR114","first-page":"267","volume":"19","author":"DJ Grignon","year":"1994","unstructured":"Grignon, D. J. & Sakr, W. A. Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? J. Cell Biochem. Suppl. 19, 267\u2013269 (1994).","journal-title":"J. Cell Biochem. Suppl."},{"key":"1112_CR115","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S0022-5347(01)66779-X","volume":"154","author":"SA Kaplan","year":"1995","unstructured":"Kaplan, S. A., Te, A. E., Pressler, L. B. & Olsson, C. A. Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J. Urol. 154, 1764\u20131769 (1995).","journal-title":"J. Urol."},{"key":"1112_CR116","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5213\/inj.2011.15.3.152","volume":"15","author":"KJ Cho","year":"2011","unstructured":"Cho, K. J., Kang, S. H., Kim, H. S., Koh, J. S. & Kim, J. C. Effect of 5-alpha reductase inhibitor on storage symptoms in patients with benign prostatic hyperplasia. Int. Neurourol. J. 15, 152\u2013157 (2011).","journal-title":"Int. Neurourol. J."},{"key":"1112_CR117","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06944145 (2025)."},{"key":"1112_CR118","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04288427 (2025)."},{"key":"1112_CR119","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/jamainternmed.2014.1600","volume":"174","author":"MA Preston","year":"2014","unstructured":"Preston, M. A. et al. 5\u03b1-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern. Med. 174, 1301\u20131307 (2014).","journal-title":"JAMA Intern. Med."},{"key":"1112_CR120","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/0008-5472.CAN-12-1335","volume":"72","author":"N Mitsiades","year":"2012","unstructured":"Mitsiades, N. et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 72, 6142\u20136152 (2012).","journal-title":"Cancer Res."},{"key":"1112_CR121","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1158\/1078-0432.CCR-17-1313","volume":"23","author":"C Dai","year":"2017","unstructured":"Dai, C. et al. Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues. Clin. Cancer Res. 23, 6351\u20136362 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1112_CR122","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature14406","volume":"523","author":"Z Li","year":"2015","unstructured":"Li, Z. et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523, 347\u2013351 (2015).","journal-title":"Nature"},{"key":"1112_CR123","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.ejca.2015.06.122","volume":"51","author":"M Shiota","year":"2015","unstructured":"Shiota, M. et al. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy. Eur. J. Cancer 51, 1962\u20131969 (2015).","journal-title":"Eur. J. Cancer"},{"key":"1112_CR124","doi-asserted-by":"publisher","first-page":"13728","DOI":"10.1073\/pnas.1107898108","volume":"108","author":"KH Chang","year":"2011","unstructured":"Chang, K. H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108, 13728\u201313733 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1112_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-020-00627-0","volume":"20","author":"A Hamid","year":"2020","unstructured":"Hamid, A. et al. Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy. BMC Urol. 20, 71 (2020).","journal-title":"BMC Urol."},{"key":"1112_CR126","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMp1106783","volume":"365","author":"MR Theoret","year":"2011","unstructured":"Theoret, M. R. et al. The risks and benefits of 5\u03b1-reductase inhibitors for prostate-cancer prevention. N. Engl. J. Med. 365, 97\u201399 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR127","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole, G. L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192\u20131202 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR128","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215\u2013224 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR129","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature17954","volume":"533","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature 533, 547\u2013551 (2016).","journal-title":"Nature"},{"key":"1112_CR130","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-096431","volume":"15","author":"M Cumberbatch","year":"2025","unstructured":"Cumberbatch, M. et al. Protocol for a randomised phase 3 trial evaluating the role of finasteride in active surveillance for men with low and intermediate-risk prostate cancer: the finesse study. BMJ Open 15, e096431 (2025).","journal-title":"BMJ Open"},{"key":"1112_CR131","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jamaoncol.2022.1501","volume":"8","author":"L Bj\u00f6rnebo","year":"2022","unstructured":"Bj\u00f6rnebo, L. et al. Association of 5\u03b1-reductase inhibitors with prostate cancer mortality. JAMA Oncol. 8, 1019\u20131026 (2022).","journal-title":"JAMA Oncol."},{"key":"1112_CR132","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/jnci\/djy036","volume":"110","author":"A Wallerstedt","year":"2018","unstructured":"Wallerstedt, A., Strom, P., Gronberg, H., Nordstrom, T. & Eklund, M. Risk of prostate cancer in men treated with 5\u03b1-reductase inhibitors \u2014 a large population-based prospective study. JNCI: J. Natl Cancer Inst. 110, 1216\u20131221 (2018).","journal-title":"JNCI: J. Natl Cancer Inst."},{"key":"1112_CR133","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fonc.2014.00247","volume":"4","author":"T Kosaka","year":"2014","unstructured":"Kosaka, T., Miyajima, A. & Oya, M. Is DHT production by 5\u03b1-reductase friend or foe in prostate cancer? Front. Oncol. 4, 247 (2014).","journal-title":"Front. Oncol."},{"key":"1112_CR134","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1677\/ERC-10-0022","volume":"17","author":"K Das","year":"2010","unstructured":"Das, K. et al. Differential expression of steroid 5\u03b1-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr. Relat. Cancer 17, 757\u2013770 (2010).","journal-title":"Endocr. Relat. Cancer"},{"key":"1112_CR135","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.eururo.2007.04.008","volume":"52","author":"O Cussenot","year":"2007","unstructured":"Cussenot, O. et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur. Urol. 52, 1082\u20131087 (2007).","journal-title":"Eur. Urol."},{"key":"1112_CR136","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ijc.22408","volume":"120","author":"VM Hayes","year":"2007","unstructured":"Hayes, V. M. et al. 5\u03b1-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int. J. Cancer 120, 776\u2013780 (2007).","journal-title":"Int. J. Cancer"},{"key":"1112_CR137","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","volume":"31","author":"R Ge","year":"2020","unstructured":"Ge, R. et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann. Oncol. 31, 470\u2013479 (2020).","journal-title":"Ann. Oncol."},{"key":"1112_CR138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229754","volume":"15","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. PLoS ONE 15, e0229754 (2020).","journal-title":"PLoS ONE"},{"key":"1112_CR139","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/pros.23052","volume":"75","author":"AM Horning","year":"2015","unstructured":"Horning, A. M. et al. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. Prostate 75, 1790\u20131801 (2015).","journal-title":"Prostate"},{"key":"1112_CR140","first-page":"9909","volume":"16","author":"A Almudimeegh","year":"2024","unstructured":"Almudimeegh, A., AlMutairi, H., AlTassan, F., AlQuraishi, Y. & Nagshabandi, K. N. Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review. Dermatol. Rep. 16, 9909 (2024).","journal-title":"Dermatol. Rep."},{"key":"1112_CR141","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1468-3083.2012.04535.x","volume":"27","author":"N Moftah","year":"2013","unstructured":"Moftah, N. et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrastructural evaluation. J. Eur. Acad. Dermatol. Venereol. 27, 686\u2013693 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1112_CR142","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/ijd.12060","volume":"53","author":"JY Jung","year":"2014","unstructured":"Jung, J. Y. et al. Effect of dutasteride 0.5 mg\/d in men with androgenetic alopecia recalcitrant to finasteride. Int. J. Dermatol. 53, 1351\u20131357 (2014).","journal-title":"Int. J. Dermatol."},{"key":"1112_CR143","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1349-7006.2007.00656.x","volume":"99","author":"M Uemura","year":"2008","unstructured":"Uemura, M. et al. Novel 5\u03b1-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 99, 81\u201386 (2008).","journal-title":"Cancer Sci."},{"key":"1112_CR144","first-page":"e30","volume":"12","author":"F Azzouni","year":"2013","unstructured":"Azzouni, F., Zeitouni, N. & Mohler, J. Role of 5\u03b1-reductase inhibitors in androgen-stimulated skin disorders. J. Drugs Dermatol. 12, e30\u2013e35 (2013).","journal-title":"J. Drugs Dermatol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01112-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01112-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01112-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:02:19Z","timestamp":1778241739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01112-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":144,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1038\/s41585-025-01112-9","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"10 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}